Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human BAY 3713372 in MTAP-deleted solid tumors
NL-OMON60074Phase 2Recruiting
- Sponsor
- Bayer
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of BAY 3713372 in Nonhematologic neoplasms (8 cohorts), sponsored by Bayer. Primary endpoints: Treatment-emergent adverse events, Treatment-emergent serious adverse events and 7 more. Started Jan 2026; status: recruiting.
02
Drugs
BAY 3713372
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON60074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60074.